Physician profile
Dane D Simons
NPI 1609876283
$3,135.47
in general payments reported to CMS, 2019-2025
34 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $286 · 2021: $411 · 2022: $548 · 2023: $752 · 2024: $479 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.56 |
| Education | $101.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $601.34 | 2019-2024 | Farxiga, Breztri |
| Abbvie INC. | $568.05 | 2021-2024 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $348.99 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $234.16 | 2019-2023 | Myrbetriq, Veozah |
| Lilly USA, LLC | $203.67 | 2021-2024 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $104.30 | 2019-2025 | Capvaxive, Gardasil 9, Steglujan |
| Pfizer INC. | $103.88 | 2023-2025 | |
| Glaxosmithkline, LLC. | $72.78 | 2022-2023 | Shingrix |
| Amgen INC. | $67.68 | 2022-2025 | Repatha, Otezla, Repatha |
| Tris Pharma INC | $67.05 | 2019-2023 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $58.20 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.71 | 2024 | Caplyta |
| Corium, LLC | $54.52 | 2024 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $47.73 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $45.80 | 2021-2023 | Seglentis |
| Paratek Pharmaceuticals, INC. | $42.17 | 2020 | |
| Idorsia Pharmaceuticals US INC | $37.07 | 2023 | Quviviq |
| Antares Pharma, INC. | $32.64 | 2022 | |
| Horizon Therapeutics Plc | $30.08 | 2019-2021 | |
| Baxter Healthcare | $25.38 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.12 | 2022 | |
| Allergan, INC. | $21.17 | 2019 | |
| Tolmar, INC. | $21.10 | 2025 | Jatenzo |
| Currax Pharmaceuticals LLC | $17.46 | 2025 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $17.05 | 2020 | |
| Sanofi Pasteur INC. | $14.59 | 2022 | |
| Esperion Therapeutics, INC. | $13.92 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.47 | 2019 | |
| Eisai INC. | $12.53 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.30 | 2021 | |
| Shire North American Group INC | $11.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dane Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.